Do patients with inflammatory bowel disease (IBD) have a higher risk of Clostridioides difficile infection compared to the general population?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, patients with inflammatory bowel disease have a substantially elevated risk of C. difficile infection compared to the general population.

Patients with IBD are approximately 5 times more likely to develop C. difficile infection than those without IBD, with a hazard ratio of 4.79. 1

Magnitude of Risk

The evidence from the 2021 ECCO guidelines clearly establishes IBD as an independent risk factor for CDI, even without traditional risk factors like antibiotic exposure or hospitalization. The data shows:

  • Community-acquired CDI: IBD patients have an odds ratio of 3.72 compared to the general population 1
  • Overall CDI risk: Approximately 5-fold increased likelihood (HR 4.79) 1
  • No difference between UC and CD: Both disease types carry similar elevated risk 1
  • Pediatric patients: The increased risk is also observed in children with IBD 1

The 2025 British Society of Gastroenterology guidelines confirm that IBD diagnosis is an independent risk factor for C. difficile infection, independent of co-prescription of PPIs or antibiotics 2. Historical data from 2007 showed CDAD rates approximately doubled in Crohn's disease (9.5 to 22.3/1000 admissions) and tripled in ulcerative colitis (18.4 to 57.6/1000 admissions) 3.

Risk Stratification Within IBD Population

Not all IBD patients carry equal risk:

  • Colonic involvement: Patients with colonic disease have OR 2.76 for developing CDI, though even those without colonic involvement still have 7% infection risk 1
  • Active disease flares: CDI occurs in 28.8% of IBD patients during flares versus 5.6% in inactive IBD and 0% in non-IBD controls (p=0.001) 1
  • Immunosuppressive therapy: Biologics (mainly anti-TNF agents) carry OR 1.65 for CDI; steroids have HR 2.54; infliximab/adalimumab have HR 2.69 1

Clinical Implications for Morbidity and Mortality

The elevated CDI risk in IBD patients translates directly into worse outcomes:

  • Short-term mortality: OR 3.84 for IBD patients with concurrent CDI 1
  • Long-term mortality: OR 3.65, with another study confirming HR 2.28 1
  • Colectomy risk: OR 2.22 for long-term colectomy 1
  • Healthcare burden: Longer hospitalizations, escalated IBD therapy, increased readmissions, and higher in-hospital expenditures 1

Common Pitfalls

Timing of presentation differs: CDI in IBD patients is confirmed predominantly within 48 hours of admission (median 0.5-0.8 days for UC/CD versus 4.0 days for non-IBD), suggesting most infections are community-acquired rather than nosocomial 3. This means you cannot rely on hospitalization as a trigger for suspicion—outpatient IBD patients with worsening symptoms require CDI screening.

Pseudomembranes are rare: Only 13% of hospitalized IBD patients with CDI show pseudomembranes on endoscopy, so their absence does not exclude infection 1. Do not use endoscopy as a diagnostic tool for CDI.

Practical Screening Approach

Based on the guidelines, screen for CDI:

  • At every disease flare in IBD patients 1
  • Especially in patients receiving immunosuppressive therapy 1
  • In mild IBD flares with rapid response to treatment, screening may not be necessary 1

The bottom line: IBD fundamentally alters a patient's risk profile for C. difficile infection, making them a high-risk population requiring heightened clinical vigilance and lower threshold for testing during any symptom exacerbation.

References

3
Research

Incidence of Clostridium difficile infection in inflammatory bowel disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007

Related Questions

In a 50-year-old woman with a history of peptic ulcer disease, systemic lupus erythematosus, and ulcerative colitis, presenting with severe Clostridioides difficile colitis (fever, hypotension, leukocytosis, thrombocytosis, rising creatinine, and colonic dilation without perforation) despite oral vancomycin, should the next step be intravenous metronidazole, escalation of oral vancomycin, fidaxomicin, or surgical intervention?
What is the complete regimen, indications, alternatives, and management for chronic relapsing diarrhea with metronidazole and diloxanide furoate?
Should antibiotics be used to treat colitis?
In a patient with 5 days of frequent diarrhea, positive fecal leukocytes and occult blood, and negative Clostridioides difficile test and routine stool cultures, what is the most appropriate next step in management?
What is the appropriate antibiotic therapy for a colitis flare-up?
Is it appropriate to repeat a dose of fosfomycin (fosfomycin trometamol) every 48 hours for an uncomplicated lower urinary tract infection?
Is levofloxacin appropriate for coverage of ulcer‑related skin and wound infections, and what are the recommended dosing and monitoring considerations?
Why did the provider choose metoprolol succinate (long‑acting β1‑selective blocker) instead of labetalol for this older adult patient with rebound hypertension after clonidine taper?
What is the role of oral Bacillus clausii?
Is amiodarone an inducer or inhibitor of cytochrome P450 enzymes?
What is the appropriate treatment for scalp folliculitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.